BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

Astrazeneca paying up to $320M to acquire individualized TCR T-cell therapy developer Neogene
Astrazeneca plc is beefing up its cell therapy capabilities in immuno-oncology by acquiring Neogene Therapeutics BV for an initial outlay of $200 million. There’s up to...

More in BioWorld

BioWorld MedTech

Boston Scientific enters bariatric market with $417M acquisition of Apollo Endosurgery
While other large med-tech companies are slimming their portfolios, Boston Scientific Corp. plans to beef its up considerably with the acquisition of Apollo Endosurgery...

More in BioWorld MedTech

BioWorld Science

Leukemia-related rogue immune cells cause autoimmune disorders
Does cancer cause autoimmune disease or is it the other way around? In looking at the question of which comes first, the chicken or the egg, researchers at the Garvan...

More in BioWorld Science

BioWorld Asia

Two deaths reported ahead of Eisai-Biogen’s presentation of phase III data on Alzheimer’s drug lecanemab
The shadow of two reported patients’ deaths hovers over Eisai Co Ltd. and Biogen Inc.’s Alzheimer’s disease treatment, lecanemab, as the companies prepare to present phase...

More in BioWorld Asia

BioWorld Insider Podcast

BioWorld staff writer Lee Landenberger talks with James Lanthier, the CEO of Mindset Pharma, which is developing what it calls “next-generation” psychedelic medicines to treat neurological and psychiatric disorders.